Microbial Colonization, Neonatal Infection, Staphylococcus Aureus
Conditions
Keywords
microbiome
Brief summary
This study aims to determine whether a parent-to-child nasal microbiota transplant (NMT) can seed and engraft parental organisms into the neonatal microbiome and increase the neonatal microbiome diversity.
Detailed description
This parent-to-child NMT study will test the effect of an anterior nares, or nasal, microbiota transplant (NMT) on seeding, engraftment, and diversity of the neonatal microbiome. Neonates admitted to the Johns Hopkins Neonatal Intensive Care Unit (NICU) will be screened and parents will be approached for enrollment in the study. After consent and baseline screening of parents and neonates, eligible neonates will undergo an NMT.
Interventions
BIOLOGICALNasal Microbiota Transplant (NMT)
nasal microbiota transplant
BIOLOGICALPlacebo
Placebo sterile swab
Sponsors
Johns Hopkins University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
0 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
Neonate: 1. Neonate has anticipated NICU length of stay \> 7 days 2. Neonate ≥25 weeks gestation 3. At least one parent/adult provider not colonized with S. aureus (as determined by baseline screening) 4. Neonate is not colonized with S. aureus on baseline screening Parent/Adult provider: 1\. Parent/Adult provider is able to provide informed consent
Exclusion criteria
Neonate: 1. Neonate has had a prior clinical or surveillance culture grow S. aureus 2. Neonate is a ward of the State 3. Neonate with antenatal suspicion for immunodeficiency (e.g. sibling with known immunodeficiency, genetic syndrome with known associated immunodeficiency) 4. Neonate cannot have nasal swabs collected (due to anatomic or other clinical intervention, including nasal packing) Parent/Adult provider: 1. Parent/adult provider had positive COVID-19 test in prior 21 days 2. Parent/adult provider with signs or symptoms of respiratory illness (e.g. runny nose, congestion, fever, cough) 3. Parent/adult provider has been in close contact with someone in the last 7 days who had a respiratory viral infection, like the cold or the flu? 4. Parent/adult provider tests positive on baseline screening test for S. aureus nasal colonization. 5. Parent/adult provider tests positive on baseline screening test for a respiratory pathogen. 6. Parent/adult provider is not able to provide written informed consent 7. Parent/adult provider is not able to be present at the bedside at the time of intervention. 8. Parent/adult provider has history of chronic sinusitis, cystic fibrosis, or an infection with a multi-drug resistant organism. 9. Inability or unwillingness to complete the Donor questionnaire or a positive response to any question on the Donor questionnaire
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neonatal nasal microbiome diversity after intervention | Day 2, 4, 7, 10, 14 days post-intervention | This outcome will be determined by analysis of periodic surveillance swabs collected after intervention. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAaron Milstone, MD
Johns Hopkins University
Outcome results
None listed